Nanjing Well Pharmaceutical Co Ltd (603351) — Working Capital to Net Assets Ratio
Nanjing Well Pharmaceutical Co Ltd (603351) has a Working Capital to Net Assets ratio of 11.3% as of September 2025. Working capital of CN¥198.70 Million (current assets of CN¥895.19 Million minus current liabilities of CN¥696.49 Million) is measured against net assets of CN¥1.77 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 603351 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Nanjing Well Pharmaceutical Co Ltd Working Capital to Net Assets (2014–2024)
This chart shows how Nanjing Well Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the ratio stands at 11.3%, reflecting working capital of CN¥198.70 Million against net assets of CN¥1.77 Billion CNY. See Nanjing Well Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Nanjing Well Pharmaceutical Co Ltd (2014–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Nanjing Well Pharmaceutical Co Ltd from 2014 to 2024, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Nanjing Well Pharmaceutical Co Ltd market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 7.1% | CN¥121.30 Million | CN¥1.71 Billion | CN¥717.21 Million | CN¥595.90 Million | ▲ +4.5 pp |
| 2023 | 2.6% | CN¥41.67 Million | CN¥1.59 Billion | CN¥599.42 Million | CN¥557.75 Million | ▲ +10.0 pp |
| 2022 | -7.4% | CN¥-109.74 Million | CN¥1.48 Billion | CN¥470.29 Million | CN¥580.02 Million | ▼ -10.4 pp |
| 2021 | 3.0% | CN¥42.00 Million | CN¥1.39 Billion | CN¥464.69 Million | CN¥422.70 Million | ▼ -11.8 pp |
| 2020 | 14.8% | CN¥192.92 Million | CN¥1.30 Billion | CN¥500.55 Million | CN¥307.63 Million | ▼ -35.5 pp |
| 2019 | 50.3% | CN¥624.31 Million | CN¥1.24 Billion | CN¥823.30 Million | CN¥198.98 Million | ▲ +27.9 pp |
| 2018 | 22.4% | CN¥137.61 Million | CN¥614.61 Million | CN¥318.25 Million | CN¥180.65 Million | ▼ -4.4 pp |
| 2017 | 26.8% | CN¥142.99 Million | CN¥532.80 Million | CN¥319.39 Million | CN¥176.40 Million | ▲ +1.9 pp |
| 2016 | 24.9% | CN¥110.71 Million | CN¥443.99 Million | CN¥256.65 Million | CN¥145.94 Million | ▲ +20.4 pp |
| 2015 | 4.5% | CN¥13.33 Million | CN¥294.49 Million | CN¥205.73 Million | CN¥192.40 Million | ▲ +0.9 pp |
| 2014 | 3.7% | CN¥8.83 Million | CN¥240.35 Million | CN¥187.64 Million | CN¥178.81 Million | — |